Robert H. Noth, MD

home / authors / robert-h-noth-md

Articles

Site Logo
June 10th 2010

Prevalence of Osteoporosis in Men in a VA Rehabilitation Center

Arthur Swislocki, MD Jon A. Green, MD, PhD Gerhard Heinrich, MD Charles A. Barnett, MD Ivan D. Meadows, MD Ernest B. Harmon, BS Mary F. Rank, RN, FNP Robert H. Noth, MD

Men in a VA rehabilitation unit who had osteoporosis were older and thinner, but otherwise similar (metabolic and functional status) to control subjects.

Site Logo
June 1st 2002

Reduction in Self-Monitoring of Blood Glucose in Persons with Type 2 Diabetes Results in Cost Savings and No Change in Glycemic Control

Joy L. Meier, PharmD Arthur L.M. Swislocki, MD Julio R. Lopez, PharmD Robert H. Noth, MD Patricia Bartlebaugh, MSN David Siegel, MD

Site Logo
January 1st 1999

Safety and Efficacy of Metformin in a Restricted Formulary

Arthur L. M. Swislocki, MD Quan Khuu Ellen Liao Emily Wu Fil Beza Julio Lopez, PharmD Gene Kwan Robert H. Noth, MD

Site Logo
October 1st 1997

Postmarketing Analysis of Lovastatin Use in the VA Northern California System of Clinics: A Retrospective, Computer-Based Study

Arthur L. M. Swislocki, MD Kim Lin Diane Cogburn, PharmD Karen Y. Fann Duke T. Khuu Robert H. Noth, MD

Latest Updated Articles

Opdivo packaging | Image credit: Bristol Myers Squibb
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com
Published: August 28th 2024 | Updated: September 7th 2024
Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy
LDL and Lp(a) | Image credit : Amgen
Published: August 4th 2024 | Updated: September 7th 2024
Who Should Have Lp(a) Levels Tested? Experts Take Sides
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Published: September 3rd 2024 | Updated: September 7th 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Published: September 3rd 2024 | Updated: September 7th 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Psoriasis | image credit: pimentos – stock.adobe.com.jpg
Published: August 28th 2024 | Updated: September 7th 2024
TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo